Coherus Oncology, Inc.
Coherus Oncology, Inc. is a U.S.-based commercial-stage oncology company focused on proprietary immuno-oncology medicines. Its core business is the commercialization of LOQTORZI (toripalimab-tpzi) and the advancement of mid-stage pipeline candidates aimed at overcoming immune resistance in cancer.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaApproved immuno-oncology therapy sold in the United States and supported by partner commercialization in Canada.
Mid-stage and early-stage oncology candidates being developed for additional cancer indications and combinations.
Exclusive regional rights, options, and milestone/royalty arrangements tied to toripalimab and related assets.
Tuotteet
Raportoitu · osuus liikevaihdosta- Toripalimab96,8 %
- Other3,2 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
The company sells primarily into the oncology treatment ecosystem, where prescribing physicians, hospitals, integrated delivery networks, and managed care organizations determine adoption and reimbursement. Demand is driven by clinical efficacy, safety, guideline placement, and payer coverage, rather than direct consumer choice. In Canada, commercialization is supported through a partner license arrangement, while the U.S. business is directly commercialized.
Medical oncologists and treatment centers that prescribe LOQTORZI based on efficacy, safety, and label fit.
Hospitals, integrated delivery networks, and cancer centers that decide formulary inclusion and treatment pathways.
Government and commercial payers that determine coverage and patient access for oncology biologics.
License and collaboration partners that help commercialize or develop assets in selected territories.
Strategia
The company’s strategy is to build LOQTORZI sales in nasopharyngeal carcinoma while expanding into new indications and combination regimens. It is also repositioning as a pure-play immuno-oncology company after divesting its biosimilar businesses and is working to strengthen supply chain control by onshoring manufacturing.
The approved product is the main revenue engine and the base for future indication expansion.
Pipeline success is needed to diversify revenue and support long-term growth beyond one marketed product.
Reducing dependence on third-party CMOs can improve supply security and commercial readiness.
Maantiede
Coherus Oncology primarily operates in the United States and measures its business as one reportable segment centered there. It also has a Canada commercialization arrangement for toripalimab, but the company states that it operates primarily in the U.S. and partners for other countries. Management is also executing a manufacturing onshoring initiative to bring production of LOQTORZI, casdozokitug, and tagmokitug to the United States.
Riskit
The business is highly dependent on a single approved product and on successful clinical, regulatory, and commercial execution for its pipeline. It also faces intense competition from larger oncology companies, payer pressure, and manufacturing/supply chain dependence on third parties. Because the company is still building scale after divesting its biosimilar businesses, funding needs and execution risk remain elevated.
- Dependence on LOQTORZIVaikutus: KorkeaTodennäköisyys: Korkea
The company has only one approved commercial product, so any launch, safety, or reimbursement setback would materially affect revenue.
Kohdistuu: Commercial revenue concentration
- Competitive pressure in immuno-oncologyVaikutus: KorkeaTodennäköisyys: Korkea
LOQTORZI competes with entrenched PD-1/PD-L1 therapies from much larger companies with stronger commercial resources.
Kohdistuu: Market share and pricing
- Clinical and regulatory failure of pipeline assetsVaikutus: KorkeaTodennäköisyys: Kohtalainen
Casdozokitug, CHS-114, and other candidates are still in development and may never reach approval.
Kohdistuu: Pipeline development
- Payer and pricing pressureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Coverage, formulary placement, and state/federal drug pricing rules can limit access and net pricing.
Kohdistuu: U.S. reimbursement
- Manufacturing and supply chain relianceVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The company relies on CMOs for commercial and clinical supply, which can create delays, quality issues, or cost inflation.
Kohdistuu: Third-party production
Kirjanpito
Harkinnanvaraiset erätNet revenue depends on estimates for rebates, chargebacks, returns, and other deductions in a payer-driven market.
Vaikutus: Can materially change reported product revenue and margins
The LOQTORZI agreement includes milestone payments and royalties that affect cost structure and cash flows.
Vaikutus: Affects gross margin and operating cash requirements
The biosimilar divestitures were classified as discontinued operations, changing how prior-period results are presented.
Vaikutus: Can distort trend analysis across years
The company disclosed fair value changes related to discontinued operations and derivative liabilities.
Vaikutus: Can introduce earnings volatility unrelated to core operations
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Tvardi Therapeutics, Inc.
TVRD · Pharmaceutical Preparations
Tvardi Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for fibrosis-driven diseases and certain cancers.
Compass Therapeutics, Inc.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
TuHURA Biosciences, Inc.
HURA · Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV is a Nevada-based clinical-stage immuno-oncology company focused on developing therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies.
Päivitetty: 24.9.2026